Search clinical trials for: IL-2

Total 16329 results

Peking University Third Hospital

Recruiting

Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome

Amyotrophic Lateral Sclerosis

China
Brigham and Women's Hospital

Terminated

Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA

Abdominal Wall Defect | Amputation, Traumatic | Amputation;Traumatic;Old | Face Injury | Face; Deformity

United States
Peking University People's Hospital

Unknown

The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients

Infection

China
jiangjingting

Unknown

Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

Lymphoma, B Cell

China
University of Chicago

Terminated

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

Melanoma | Neoplasm Metastasis

United States
National Cancer Institute (NCI)

Completed

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
University of Minnesota

Completed

Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2

HIV

United States
National Cancer Institute (NCI)

Terminated

Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

Sarcoma | Breast Neoplasm | Lung Neoplasm | Kidney Neoplasm

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers (HEALTHIL-2)

Healthy Volunteers

France
Iovance Biotherapeutics, Inc.

Recruiting

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Oxford BioMedica
The Methodist Hospital Research Institute; ORION Clinical Services

Completed

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Carcinoma, Renal Cell

United States
Iltoo Pharma

Completed

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) (LUPIL-2)

Systemic Lupus Erythematosus

France, Spain, Mexico, Austria, Germany, Bulgaria, Italy, Mauritius, Portugal, Romania
Vical

Completed

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

Metastatic Melanoma

United States
National Cancer Institute (NCI)

Completed

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Rhabdomyosarcoma | Ewing's Sarcoma

United States
Belarusian Research Center for Pediatric Oncology...

Completed

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Leukemia, Acute Lymphoblastic | Leukemia, Acute Myeloid

Belarus
BioNTech US Inc.

Recruiting

NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

Belgium, Netherlands, Spain
OncBioMune Pharmaceuticals
United States Department of Defense

Unknown

Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (PSA)

Prostate Cancer

United States
Jeffrey Bluestone
Yale University

Completed

T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT)

Type 1 Diabetes Mellitus

United States
Peking University People's Hospital
Monash University; Beijing ShuangLu Pharmaceutical Co., Ltd.

Unknown

A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Fuzhou General Hospital

Unknown

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

China
Oslo University Hospital

Completed

Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma

Malignant Melanoma
AgonOx, Inc.
Providence St Joseph Health; Phio Pharmaceuticals Corp.

Recruiting

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (ACT)

Melanoma | Gynecologic Cancer | Colorectal Cancer | Lung Cancer | HNSCC | Urogenital Cancer

United States
University Hospital, Limoges

Withdrawn

Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study (NIL-2 pilote)

Nephrotic Syndrome Steroid-Dependent | Interleukin 2
Instituto Nacional de Enfermedades Respiratorias

Unknown

Renal Biomarkers in AKI and COVID-19

Coronavirus Infection | Covid19 | AKI | SARS (Severe Acute Respiratory Syndrome)

Mexico
Dartmouth-Hitchcock Medical Center

Completed

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

Leukemia | Multiple Myeloma | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)

United States
Gregory Daniels

Recruiting

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

Melanoma Stage Iv | Renal Cell Carcinoma, Metastatic

United States
HeJing

Completed

Low-dose IL-2 Treatment on Behcet's Disease

Behcet's Disease

China
Mansoura University

Completed

Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers

Bladder Cancer

Egypt
Centre Hospitalier Universitaire de Nīmes

Completed

Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder (HYCOIN)

Conversion Disorder

France
Peking University People's Hospital
Monash University; Beijing ShuangLu Pharmaceutical Co., Ltd.

Completed

A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

China
Century Therapeutics, Inc.

Not yet recruiting

A Study of CNTY-101 in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) (CALiPSO-1)

Systemic Lupus Erythematosus
ImmunityBio, Inc.

Completed

QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

United States
Sheba Medical Center

Unknown

Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Metastatic Ovarian Cancer

Israel
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells (PRIMAL)

Chronic Lymphocytic Leukemia (CLL)

United States
The First People's Hospital of Changzhou

Not yet recruiting

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

Renal Neoplasma
University of Virginia

Completed

Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma (MEL36)

Melanoma
Riphah International University
KRL Hospital, Islamabad

Recruiting

Diagnostic and Prognostic Blood Markers in Non Specific Low Back Pain

Low Back Pain

Pakistan
Biohaven Pharmaceuticals, Inc.
Dana-Farber Cancer Institute

Recruiting

Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients

Multiple Myeloma

United States
Istituto Scientifico Romagnolo per lo Studio e...

Withdrawn

Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC (RENALVax-2)

Carcinoma, Renal Cell | Secondary | Vaccination

Italy
Providence Health & Services
Prometheus Laboratories

Active, not recruiting

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. (SBRT/IL-2)

Metastatic Melanoma

United States
Zhejiang University
Zcapsule Pharmaceuticals (Shaoxing) Co., Ltd

Recruiting

The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

Ovarian Cancer | Bladder Cancer | Small-cell Lung Cancer | Liver Cancer | Esophagus Cancer

China
Istituto Scientifico Romagnolo per lo Studio e...

Unknown

Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 (IL2HD)

Metastatic Renal Cell Cancer | Malignant Melanoma, Metastatic

Italy
Century Therapeutics, Inc.

Recruiting

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)

Aggressive Non-Hodgkin Lymphoma | R/R CD19-Positive B-Cell Malignancies | Indolent Non-Hodgkin Lymphoma

United States
Technical University of Munich

Completed

Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

NSCLC Stage IIIA/B

Germany
MycoMedica Life Sciences PBC

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

Healthy Volunteers

Australia
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation

MDS | Chronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML)

United States
Sun Yat-sen University

Unknown

A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors

Nasopharyngeal Carcinoma | Hepatocellular Carcinoma | Breast Carcinoma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Withdrawn

Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells (CLONTAK)

CHRONIC LYMPHOCYTIC B-LEUKEMIA
Megan Daly, MD
Merck Sharp & Dohme LLC

Recruiting

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Metastatic Renal Cell Carcinoma | Non Small Cell Lung Cancer | Metastatic Melanoma | Head and Neck Squamous Cell Carcinoma

United States

Search clinical trials for: IL-2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations